Yoshishige Samukawa

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria

Yukihiro Chino, Yoshishige Samukawa, Soichi Sakai et al. · Biopharmaceutics & Drug Disposition · 2014 · 386 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study

Yutaka Seino, Takashi Sasaki, Atsushi Fukatsu et al. · Current Medical Research and Opinion · 2014 · 148 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus

Masakazu Haneda, Yutaka Seino, Nobuya Inagaki et al. · Clinical Therapeutics · 2015 · 85 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study

Yutaka Seino, Takashi Sasaki, Atsushi Fukatsu et al. · Current Medical Research and Opinion · 2014 · 63 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials

Soichi Sakai, Kohei Kaku, Yutaka Seino et al. · Clinical Therapeutics · 2016 · 63 citations

Medicine, Pharmacology, Pharmacotherapy +17